Your Kid's ADHD and Depression Aren't Two Separate Problems. They're One Blueprint.
Key Findings
Using a statistical technique called MiXeR - which estimates the overlap between genetic architectures - the researchers found that fewer than 1% of the causal variants for ADHD are ADHD-specific. The rest are shared with major depressive disorder (MDD) and/or bipolar disorder (BPD). This wasn't a minor overlap. The conditions share the vast majority of their genetic foundations.
To put numbers on it: the study estimated thousands of causal variants for ADHD, and most of them also influence depression or bipolar. The conditions aren't genetically distinct - they're genetically entangled.
Across 510,491 cases, the study identified 350 independent genomic loci associated with the shared factor across all three conditions - 105 of which are novel. That's a substantial haul for a single study, though most of these loci will need replication before anyone builds clinical tools around them.
The study also found 2,936 novel gene associations through a brain-specific analysis method, adding texture to where in the genome these signals live.
When the researchers asked "where in the brain are these genes active?", the answers pointed consistently to dopamine neurons and synaptic connections - the same systems implicated in each condition individually. The genetic architecture isn't random; it's concentrated in the brain's reward and communication infrastructure.
A secondary finding worth noting: the cerebellum showed up as an enriched region. That's less expected and potentially interesting - the cerebellum's role in ADHD and mood disorders is an active research area that doesn't get as much attention as the prefrontal cortex.
The strongest single-gene signal in the study was PTPRD (protein tyrosine phosphatase receptor delta), with an association p-value of 2x10^-16. PTPRD is involved in synapse formation and dopamine neuron development.
Mouse knockout studies show that animals without functional PTPRD display hyperactivity and impulsivity patterns. That's suggestive, but this is still a candidate gene - not a confirmed mechanism. Years of functional validation in humans would be needed before PTPRD became the basis for any clinical application.
Why It Matters
Most families navigating ADHD plus depression or bipolar feel like they're fighting on multiple fronts. Different diagnoses, different specialists, different medications, different waitlists. The implicit message from the healthcare system is: your child has several separate problems that happen to coexist.
This research suggests that framing is wrong. When ADHD travels with depression or bipolar - which it does frequently - it's likely because they share the same underlying genetic architecture. The conditions aren't separate entities that both decided to show up. They're different expressions of the same wiring.
That matters practically. It's an argument for integrated care - clinicians who treat the whole picture rather than each diagnosis in isolation. It's also an argument for families to stop blaming themselves or feeling like they drew a particularly bad hand. The genome doesn't recognize the boxes we've drawn between diagnoses. It's doing one thing that looks like several.
And one more thing: this is your child's neurotype, not their prognosis. Shared wiring isn't a sentence. It's an architecture - and architecture can be worked with.
The Fine Print
All three constituent GWAS datasets (iPSYCH, PGC, deCODE) draw overwhelmingly from European-ancestry populations. The genetic architecture of ADHD, depression, and bipolar may differ across ancestry groups.
We covered this exact problem with autism genetics in Issue #1. The field keeps finding things in European data and calling them universal. The PTPRD finding especially - a candidate drug target - needs replication in diverse ancestry groups before anyone should get excited about clinical applications.
The three datasets weren't equal partners. Major depression contributed the largest sample by far, giving it roughly 80%+ of the statistical power in the combined analysis. When a multivariate analysis is this imbalanced, the "shared factor" it identifies will inevitably look a lot more like depression than like ADHD or bipolar.
The authors acknowledge this but don't fully resolve it. The less-than-1% unique ADHD variants finding is real, but its magnitude may partly reflect the analysis being depression-dominant rather than a pure characterization of ADHD's genetic architecture.
The paper's PTPRD narrative is built on mouse knockout studies and GWAS association, which is a reasonable starting point. But association is not mechanism. Many highly significant GWAS hits from the past decade turned out to be in gene regulatory regions with complex downstream effects that didn't pan out into drug targets.
PTPRD may prove important. It may also follow the long tail of "interesting candidate genes" that never become clinically relevant. Hold this one loosely.
What to Do With This
Stop treating comorbidities as separate problems to be managed separately. If your child has ADHD plus depression or anxiety, the research increasingly supports that these aren't independent conditions that both decided to visit your family. They share genetic roots. A clinician who treats them as isolated silos may be missing the picture.
Ask for integrated care when you can get it. Psychiatrists and psychologists who are comfortable with the full ADHD-mood picture - rather than specialists who only see one diagnosis at a time - are more likely to find interventions that address the shared architecture rather than just one symptom cluster.
Take the biology seriously as a framing tool. "My child's brain is wired this way" is both accurate and more useful than "my child has these three problems." It shifts the conversation from blame to support - for your child and for yourself.
The genetic evidence for transdiagnostic approaches is accumulating. When a patient presents with ADHD plus depressive episodes or mood instability, this research supports treating the presentation as a coherent whole rather than addressing diagnoses sequentially.
Track the PTPRD literature if you're in research or pharmacology. The association is strong, the mouse data is suggestive, and the pathway (synapse formation, dopamine regulation) is biologically coherent. It's 5-10 years from clinical relevance at minimum, but worth watching.
The full dataset and analysis scripts are publicly available. The Zenodo repository has the GWAS summary statistics, and the GitHub repo has the analysis code if you want to dig into the MiXeR methodology yourself.
The genomic SEM framework used here - which models latent genetic factors across multiple conditions simultaneously - is becoming one of the more powerful tools in psychiatric genetics. Worth understanding if you're following this space.